In this report in an animal model the drug Rapamycin was shown to be helpful in reversing emphysema to at least some degree. This drug has other beneficial properties that may also help stop and to help repair damaged lungs since it has been also shown to inhibit the absorption and action of certain toxins present in all of us and that have been shown to contribute to the pathology of emphysema (gram negative bacterial lipopolysaccharides).
Reports on Pulmonary Emphysema from Monash University Provide New Insights (Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema)
Obesity, Fitness & Wellness Week. (Jan. 21, 2017): p5500.
Copyright: COPYRIGHT 2017 NewsRX LLC
2017 JAN 21 (NewsRx) — By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week — A new study on Lung Diseases and Conditions – Pulmonary Emphysema is now available. According to news reporting originating in Clayton, Australia, by NewsRx journalists, research stated, “The potent immunomodulatory cytokine IL-6 is consistently up-regulated in human lungs with emphysema and in mouse emphysema models; however, the mechanisms by which IL-6 promotes emphysema remain obscure. IL-6 signals using two distinct modes: classical signaling via its membrane-bound IL-6 receptor (IL-6R), and trans-signaling via a naturally occurring soluble IL-6R.”
The news reporters obtained a quote from the research from Monash University, “To identify whether IL-6 trans-signaling and/or classical signaling contribute to the pathogenesis of emphysema. We used the gp/30(F/F) genetic mouse model for spontaneous emphysema and cigarette smoke induced emphysema models. Emphysema in mice was quantified by various methods including in vivo lung function and stereology, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay was used to assess alveolar cell apoptosis. In mouse and human lung tissues, the expression level and location of I-L-6 signaling related genes and proteins were measured, and the levels of IL-6 and related proteins in sera from emphysematous mice and patients were also assessed. Lung tissues from patients with emphysema, and from spontaneous and cigarette smoke induced emphysema mouse models, were characterized by excessive production of soluble IL-6R Genetic blockade of IL-6 trans-signaling in emphysema mouse models and therapy with the IL-6 trans-signaling antagonist sgp130Fc ameliorated emphysema by suppressing augmented alveolar type II cell apoptosis. Furthermore, IL-6 trans-signaling driven emphysematous changes in the lung correlated with mechanistic target of rapamycin complex 1 hyperactivation, and treatment of emphysema mouse models with the mechanistic target of rapamycin complex 1 inhibitor rapamycin attenuated emphysematous changes.”
According to the news reporters, the research concluded: “Collectively, our data reveal that specific targeting of IL-6 trans-signaling may represent a novel treatment strategy for emphysema.”
For more information on this research see: Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema. American Journal of Respiratory and Critical Care Medicine, 2016;194(12):1494-1505. American Journal of Respiratory and Critical Care Medicine can be contacted at: Amer Thoracic Soc, 25 Broadway, 18 Fl, New York, NY 10004, USA.
Our news correspondents report that additional information may be obtained by contacting B.J. Jenkins, Monash University, Fac Med Nursing & Hlth Sci, Dept. of Mol Translat Sci, Clayton, Vic, Australia. Additional authors for this research include L. McLeod, L.F. Dousha, H.J. Seow, S. Alhayyani, M.D. Tate, V. Deswaerte, G.D. Brooks, S. Bozinovski, M. MacDonald, C. Garbers, P.T. King, P.G. Bardin, R. Vlahos, S. Rose-John, G.P. Anderson and B.J. Jenkins.
Keywords for this news article include: Clayton, Australia, Australia and New Zealand, Respiratory Tract Diseases and Conditions, Lung Diseases and Conditions, Pulmonary Emphysema, Therapeutics, Genetics, Therapy, Monash University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Source Citation (MLA 8th Edition)
“Reports on Pulmonary Emphysema from Monash University Provide New Insights (Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema).” Obesity, Fitness & Wellness Week, 21 Jan. 2017, p. 5500. Health Reference Center Academic,